Pan-ELR+ CXC CHEMOKINE ANTIBODIES
AssigneeEli Lilly and Company
InventorsCatherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
Life of this patent
Estimating the term…
Abstract
Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
Claims18
An antibody that binds human Gro-alpha, Gro-beta, Gro-gamma, ENA-78, GCP-2, NAP-2, and IL-8, the antibody comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises LCDR1, LCDR2, LCDR3 and the HCVR comprises HCDR1, HCDR2, HCDR3, wherein LCDR1 is RASQSISNNLH (SEQ ID NO:
- 7), LCDR2 is YTSRSVS (SEQ ID NO:
- 8), LCDR3 is GQNNEWPEV (SEQ ID NO:
- 9), HCDR1 is GYEFTSYWIH (SEQ ID NO:
- 10), HCDR2 is NISPNSGSANYNEKFKS (SEQ ID NO:
- 11), and HCDR3 is EGPYSYYPSRXaaYYGSDL (SEQ ID NO:
- 20) wherein Xaa is E or Q.
A DNA molecule comprising a polynucleotide sequence encoding a first polypeptide having the amino acid sequence of SEQ ID NO:
- 1 or 13;
- and comprising a second polynucleotide sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO:
- 3 or 15.
Dependencies are inferred from the claim text.